STING1 and breast neoplasm: In the case of tumors like breast tumors that poorly respond to anti-PD1/PDL1 checkpoint inhibitors and in which TGFβ and M2-like macrophages are abundant21,36, there would be a solid rationale for using a triple combination of anti-TGFβ, anti-PD-1 and a third partner, such as STING agonist or chemotherapy.